4//SEC Filing
Nash Huw M. 4
Accession 0001415889-24-008686
CIK 0001623526other
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 8:31 PM ET
Size
9.7 KB
Accession
0001415889-24-008686
Insider Transaction Report
Form 4
Nash Huw M.
COO & CBO
Transactions
- Sale
Common Stock
2024-03-19$6.10/sh−4,116$25,102→ 11,329 total - Exercise/Conversion
Common Stock
2024-03-15+13,100→ 15,445 total - Exercise/Conversion
Restricted Stock Units
2024-03-15−13,100→ 39,300 totalExp: 2027-03-15→ Common Stock (13,100 underlying)
Footnotes (5)
- [F1]The reported total includes an aggregate 2,345 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
- [F2]The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.94 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
- [F5]The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.
Documents
Issuer
Stoke Therapeutics, Inc.
CIK 0001623526
Entity typeother
Related Parties
1- filerCIK 0001780085
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 8:31 PM ET
- Size
- 9.7 KB